clinical trial · NCT06646289
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
Janssen Research & Development, LLC·phase2·active not recruiting·n = 24
X-Linked Retinitis PigmentosaAAV5-hRKp.RPGRNo intervention (Follow-Up assessment)
brief summary
The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.
started
Oct 10, 2024
primary completion
Oct 24, 2030
completion
Oct 24, 2030
last updated
Apr 13, 2026
official title
An Open-label, Multicenter, Phase 2 Follow-on Study for Second Eye Treatment of Patients Previously Treated With a Recombinant Adeno-associated Virus Vector (AAV5 hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol